Replies to post #226881 on Biotech Values

[DewDiligence]

FGEN—Astute observation regarding the hazy distinction between primary and ancillary analyses when the agreement with the regulator is post-hoc.

Just to be clear: the excerpt you posted is from p28 of FGEN’s 3Q19 10-Q, which was filed yesterday (https://www.sec.gov/ix?doc=/Archives/edgar/data/921299/000156459019042615/fgen-10q_20190930.htm ).